Loading
NASDAQHealthcareBiotechnology
Latest quote
$183.4
−$17.469 · -8.70%
Revolution Medicines, Inc. is a precision oncology firm operating in the clinical development stage, dedicated to creating innovative treatments that target novel pathways crucial for RAS-driven cancers. Its pipeline includes several promising drug candidates: RMC-4630, an SHP2 inhibitor, is currently undergoing Phase 1/2 clinical trials for various solid tumors, such as gynecological and colorectal cancers. The company's portfolio also features RMC-5845, a selective inhibitor designed to target SOS1, a protein responsible for activating RAS within cells, and RMC-5552, a highly selective inhibitor for hyperactive mTORC1 signaling found in cancerous cells. Further expanding its therapeutic arsenal, Revolution Medicines is advancing RMC-6291, which selectively inhibits mutated forms of KRASG12C(ON) and NRASG12C(ON). Another promising compound, RMC-6236, specifically targets and inhibits a range of active RAS(ON) variants. Its research efforts also encompass other active RAS inhibitors aimed at KRASG13C(ON) and KRASG12D(ON) mutations. Revolution Medicines has established a collaborative partnership with Sanofi to research and develop SHP2 inhibitors, a collaboration that includes the development of RMC-4630. Established in 2014, Revolution Medicines, Inc. operates from its corporate headquarters situated in Redwood City, California.
Regular session
$183.4
−$17.469 · -8.70%
Regular session · ET · Market data may be delayed.
Revolution Medicines, Inc. is a precision oncology firm operating in the clinical development stage, dedicated to creating innovative treatments that target novel pathways crucial for RAS-driven cancers. Its pipeline includes several promising drug candidates: RMC-4630, an SHP2 inhibitor, is currently undergoing Phase 1/2 clinical trials for various solid tumors, such as gynecological and colorectal cancers. The company's portfolio also features RMC-5845, a selective inhibitor designed to target SOS1, a protein responsible for activating RAS within cells, and RMC-5552, a highly selective inhibitor for hyperactive mTORC1 signaling found in cancerous cells. Further expanding its therapeutic arsenal, Revolution Medicines is advancing RMC-6291, which selectively inhibits mutated forms of KRASG12C(ON) and NRASG12C(ON). Another promising compound, RMC-6236, specifically targets and inhibits a range of active RAS(ON) variants. Its research efforts also encompass other active RAS inhibitors aimed at KRASG13C(ON) and KRASG12D(ON) mutations. Revolution Medicines has established a collaborative partnership with Sanofi to research and develop SHP2 inhibitors, a collaboration that includes the development of RMC-4630. Established in 2014, Revolution Medicines, Inc. operates from its corporate headquarters situated in Redwood City, California.
Day range
Current $183.4
52-week range
Current $183.4
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
31
Expensive
Sentiment
56
Mixed
Risk
35
Moderate Risk
Momentum
65
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Revolution Medicines, Inc. is a precision oncology firm operating in the clinical development stage, dedicated to creating innovative treatments that target novel pathways crucial for RAS-driven cancers. Its pipeline includes several promising drug candidates: RMC-4630, an SHP2 inhibitor, is currently undergoing Phase 1/2 clinical trials for various solid tumors, such as gynecological and colorectal cancers. The company's portfolio also features RMC-5845, a selective inhibitor designed to target SOS1, a protein responsible for activating RAS within cells, and RMC-5552, a highly selective inhibitor for hyperactive mTORC1 signaling found in cancerous cells. Further expanding its therapeutic arsenal, Revolution Medicines is advancing RMC-6291, which selectively inhibits mutated forms of KRASG12C(ON) and NRASG12C(ON). Another promising compound, RMC-6236, specifically targets and inhibits a range of active RAS(ON) variants. Its research efforts also encompass other active RAS inhibitors aimed at KRASG13C(ON) and KRASG12D(ON) mutations. Revolution Medicines has established a collaborative partnership with Sanofi to research and develop SHP2 inhibitors, a collaboration that includes the development of RMC-4630. Established in 2014, Revolution Medicines, Inc. operates from its corporate headquarters situated in Redwood City, California.
Day range
Current $183.4
52-week range
Current $183.4
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | — | 11.58M USD | 35.38M USD | 29.39M USD |
| Cost of goods sold | 16.56M USD | — | — | — | — |
| Gross profit | −16.56M USD | — | 11.58M USD | 35.38M USD | 29.39M USD |
| Research and development | 978.68M USD | 592.23M USD | 423.14M USD | 253.07M USD | 186.95M USD |
| Selling, general, and administrative | 187.13M USD | 97.3M USD | 75.62M USD | 40.59M USD | 30.45M USD |
| Operating expenses | 1.17B USD | 689.52M USD | 498.77M USD | 293.66M USD | 217.4M USD |
| Interest income | 90.69M USD | 86.88M USD | 47.48M USD | 9.15M USD | 929K USD |
| Interest expense | 24.23M USD | — | 303K USD | — | 12K USD |
| Depreciation and amortization | 16.56M USD | 11.82M USD | 9.31M USD | 9.66M USD | 7.33M USD |
| Operating income | −1.18B USD | −689.52M USD | −487.19M USD | −258.28M USD | −188.01M USD |
| Net income | −1.13B USD | −600.09M USD | −436.37M USD | −248.71M USD | −187.09M USD |
Company facts updated Oct 8, 2026.
Third-party consensus; not a GoAI recommendation.
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI1.32B0.06%2.3T USD0.03%$379.16-0.49%
Vanguard Morningstar Small-Cap ETFVB955.33M0.51%185.3B USD0.03%$285.82-0.40%
Vanguard Morningstar Small-Cap Growth ETFVBK548.26M1.20%44.7B USD0.05%$338.96-0.96%
Vanguard Extended Market ETFVXF477.27M0.49%95.4B USD0.05%$231.86-0.70%
iShares Biotechnology ETFIBB292.96M2.81%10.4B USD0.44%$197.69-2.78%
iShares Russell Mid-Cap Growth ETFIWP216.57M1.09%20.14B USD0.23%$140.59-0.62%
iShares Russell Mid-Cap ETFIWR159.12M0.28%56.57B USD0.18%$108.24-0.21%
State Street SPDR S&P Biotech ETFXBI146.9M1.46%10.08B USD0.35%$146.58-2.43%Vanguard Morningstar Total Stock Market ETFVTIVanguard Morningstar Small-Cap ETFVBVanguard Morningstar Small-Cap Growth ETFVBKVanguard Extended Market ETFVXFiShares Biotechnology ETFIBBiShares Russell Mid-Cap Growth ETFIWPiShares Russell Mid-Cap ETFIWRState Street SPDR S&P Biotech ETFXBIAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
